Kolkata: West Bengal faces a formidable cancer challenge, with a staggering burden exacerbated by high tobacco usage, particularly among men. The state’s lung cancer incidence is 26.6% higher than the national average, underscoring the urgent need for comprehensive cancer care. Fortunately, recent advancements offer hope, spotlighting precision therapies and personalized care as key strategies for tackling this complex issue.
One groundbreaking development is the introduction of CAR-T cell therapy, specifically NexCAR19, in West Bengal. This gene-modified cell treatment represents a significant leap forward in precision therapy for cancer, offering a single-infusion approach that not only improves the quality of life for patients but also comes at a fraction of the global cost. CAR-T therapy presents a new era of personalized cancer care, providing potential solutions for patients with relapsed or refractory B-cell lymphoma and B-acute lymphoblastic leukaemia.
While technology plays a vital role, personalized cancer care requires more than just cutting-edge treatments. Enter Medix Global, a company aiming to revolutionize healthcare delivery in India. Offering a unique healthcare management model, Medix emphasizes the importance of personalized cancer care case management services. Ms. Sigal Atzmon, Founder and CEO of Medix Global, notes, “No two cancer journeys are identical,” highlighting the need for tailored services that delve into medical history, personal circumstances, and treatment goals to craft precise and personalized care plans for each patient.
Dr. Ankit Kumar Gupta, Senior Case Manager Doctor at Medix Global’s Mumbai Office, stresses how their model signifies a departure from the one-size-fits-all approach towards a more advanced, nuanced, patient-specific, and holistic cancer care system. “By implementing our uniquely managed care models across India, Medix flattens the inequality of care curve, making quality healthcare borderless,” he says. Medix Global’s impact is evident in its ability to change diagnoses, recommend optimal treatment regimens, and help patients avoid unnecessary procedures, showcasing the tangible benefits of personalized cancer management.
According to Ms. Atzmon, “In 7.8% of the oncology cases managed, we changed the diagnosis and helped reach an accurate diagnosis. In 54.1% of the cases, our specialists have recommended a different and more optimal, personalized treatment regimen.” This not only leads to better patient outcomes but also contributes to the sustainability of healthcare systems by avoiding unnecessary treatments and procedures.
Personalized Cancer Management emerges as a transformative approach not only for better patient outcomes but also for the overall sustainability of healthcare systems. These innovative healthcare models present opportunities for individuals, insurers, employers, and healthcare providers to ensure a healthier, more sustainable future.
About Medix
Medix, since its inception in 2006, has been at the forefront of transforming healthcare delivery by leveraging cutting-edge science, expertise, treatments, and technology. Operating globally in more than 90 countries, Medix focuses on providing personalized and data-driven medical responses to critical health needs. Their commitment to better health outcomes, combined with a shared value approach, positions Medix as a key player in driving social and economic growth in the communities they serve while ensuring improved medical and human outcomes.
